Two case reports of severe myocarditis associated with the initiation of dolutegravir treatment in HIV patients

Medicine (United States)

Volumn 95, Issue 47, 2016, Pages

  Mahlab Guri, Keren ^a   Asher, Ilan ^a   Rosenberg Bezalel, Shira ^a   Elbirt, Daniel ^a   Burke, Michael ^a   Sthoeger, Zev M ^a  

^a KAPLAN MEDICAL CENTER   (Israel)

Author keywords

Dolutegravir; HIV treatment; Myocarditis

Indexed keywords

ABACAVIR; ABACAVIR PLUS DOLUTEGRAVIR PLUS LAMIVUDINE; ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; CD20 ANTIGEN; CD3 ANTIGEN; CREATINE KINASE; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; DIGOXIN; DIURETIC AGENT; DOBUTAMINE; DOLUTEGRAVIR; EFAVIRENZ; EMTRICITABINE; LACTATE DEHYDROGENASE; LAMIVUDINE; LEVOTHYROXINE; LOPINAVIR PLUS RITONAVIR; METFORMIN; RALTEGRAVIR; TECHNETIUM 99M; TENOFOVIR; TROPONIN T; FUSED HETEROCYCLIC RINGS; INTEGRASE INHIBITOR;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; B LYMPHOCYTE; CARDIOVASCULAR MORTALITY; CASE REPORT; CD4 LYMPHOCYTE COUNT; CONGESTIVE HEART FAILURE; CORONARY ARTERY OBSTRUCTION; CREATINE KINASE BLOOD LEVEL; CYTOPATHOGENIC EFFECT; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ECHOCARDIOGRAPHY; EXTRACORPOREAL OXYGENATION; FEMALE; FEVER; FUNCTIONAL DISEASE; HEART CATHETERIZATION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HEART MUSCLE NECROSIS; HEART VENTRICLE FUNCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPOTHYROIDISM; IMMUNOHISTOCHEMISTRY; INTUBATION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LEG EDEMA; LYMPHOCYTE SUBPOPULATION; MALE; MIDDLE AGED; MYOCARDITIS; PRIORITY JOURNAL; PROTEINURIA; SLEEP DISORDER; T LYMPHOCYTE; THROMBOCYTOPENIA; VIRUS LOAD; CHEMICALLY INDUCED; FATALITY; HIV INFECTIONS;

FATAL OUTCOME; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; MYOCARDITIS;

EID: 85006007563     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000005465     Document Type: Article

References (14)

1. Dow DE, Bartlet JA. Dolutegravir, the second-generation of integrase strand transfer inhibitors (INSTIs) for the treatment of HIV. Infect Dis Ther 2014;3:83-102.
2. Van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012;12:111-8.
3. Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 2013;382:700-8.
4. Molina JM, Clotet B, van Lunzen J, et al. FLAMINGO Study Team Once-daily dolutegravir versus darunavir plus ritonavir for treatmentnaive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV 2015;2:e127-36.
5. Günthard HF, Aberg JA, Eron JJ, et al. International Antiviral Society-USA Panel Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 2014;312:410-25.
6. Behrens GM1, Reiss P. Abacavir and cardiovascular risk. Curr Opin Infect Dis 2010;23:9-14. 2.
7. Mededdu G, VL De Socio G, Ricci E, et al. Muscle symptoms and creatinine phosphokinase elevations in patients receiving raltegravir in clinical practice: results from SCOLTA project long-term surveillance. Int J Antimicrob Agents 2015;45:289-94.
8. Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavirlamivudine for the treatment of HIV-1 infection. N Engl J Med 2013; 19:1807-18. 369.
9. Kulkosky J, Jones KS, Katz RA, et al. Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases. Mol Cell Biol 1992;12:2331-8.
10. Morita M, Stamp G, Robins P, et al. Gene-targeted mice lacking the Trex1 (DNase III) 30->50 DNA exonuclease develop inflammatory myocarditis. Mol Cell Biol 2004;24:6719-27.
11. Stetson DB, Volkman HE. The enemy within: endogenous retroelements and autoimmune disease. Nature Immunol 2014;15:415-22.
12. Beck-Engeser GB, Eilat D, Harrer T, et al. Early onset of autoimmune disease by the retroviral integrase inhibitor raltegravir. Proc Natl Acad Sci U S A 2009;106:20865-70.
13. Stetson DB. Endogenous retroelements and autoimmune disease. Curr Opin Immunol 2012;24:692-7.
14. Beck-Engeser GB, Eilat D, Wabl M. An autoimmune disease prevented by antiretroviral drugs. Retrovirology 2011;8:91.